Archive
1250 articles, sorted by publication time.
A battery-free wireless microneedle operated continuously for 12 hours on freely moving rats, recording molecular fluctuations associated with stress, feeding, and circadian rhythms; moving from animal experiments to human monitoring still requires overcoming hurdles in accuracy, durability, and clinical significance.
After ProSense was authorized for certain older patients with low-risk breast cancer, the first US study center is now officially in place; this five-year follow-up will examine whether the tradeoff for avoiding surgical excision falls within an acceptable range.
The new drug acts simultaneously on norepinephrine, dopamine, and serotonin signaling systems, adding a once-daily option for adults and children aged six and older; however, suicidal ideation in children, decreased appetite, and the risk of stimulant abuse are also included in the most prominent safety warnings.
A six-month pooled analysis of 136 patients found no cases of edema-type ARIA and an imaging abnormality rate of 4.4%; however, the treatment and placebo groups have not yet been separated, so neither a safety advantage nor efficacy can be concluded from these results.
In a 100-person, 24-week randomized trial, the dual-receptor agonist pemvidutide significantly reduced heavy drinking days, with multiple secondary measures also pointing to a consistent effect; however, gastrointestinal side effects, the limited sample size, and topline data that have not yet undergone peer review remain key issues for further validation.
The expert committee was not persuaded by the statistical results produced under the revised analysis; the nonbinding vote leaves Capricor facing a steeper approval hurdle ahead of the August 22 review deadline.
A human expert-supervised multi-agent AI proposed and conducted five studies using more than 50 TB of sleep signals. Among the findings, weaker coupling among physiological networks such as the brain and heart was associated with subsequent diagnoses of Parkinson’s disease and Alzheimer’s disease, but is not yet sufficient for clinical prediction.
RP1 combined with Opdivo recorded a 33.6% response rate in a single-arm trial, but the FDA believes the assessment method incorporated the local effects of direct injection and could not clarify the respective contributions of the two therapies; this dispute over evidentiary standards will be reviewed by an expert committee.
The SIE platform separates the catalytic ribozyme and RNA substrate into two components, enabling both the production of long, chemically modified circular RNA and the recovery of the catalytic component. Cell and mouse experiments showed that the products can express proteins normally, but purity, cost, and safety at industrial scale remain to be validated.
MIRA does more than answer medical questions: within a virtual electronic health record, it can take patient histories, order tests, interpret results, and arrange treatment. More than 500 retrospective cases demonstrate its potential while also exposing critical gaps in test utilization, comparison scale, and real-world validation.
Two p-tau217 blood tests identified amyloid in the brains of 39 adults with Down syndrome and no symptoms of dementia with approximately 90% accuracy; the findings could simplify clinical trial recruitment, but population-specific cutoff values still require validation in larger studies.
Spectrum-FISH extracts RNA from fresh tissue while preserving its original coordinates, using fluorescence decoding to reveal spatial differences in mRNA, microRNA, and RNA methylation. Results from mouse brains and human colorectal biopsies demonstrate its potential, but larger-scale validation is still needed before routine diagnostic use.